What prednisone dose and treatment duration are recommended for uveitis?

Prednisone Dosing for Uveitis

For noninfectious uveitis, initiate oral prednisone at 0.5-1 mg/kg/day (typically 40-60 mg daily for adults), administered as a single morning dose before 9 am, and taper to ≤7.5 mg/day within 3-4 months while transitioning to steroid-sparing immunosuppressive therapy if unable to achieve this target. 1

Initial Dosing Strategy

The FDA-approved dosing range for prednisone is 5-60 mg per day depending on disease severity 1. For uveitis specifically:

• Starting dose: Most cases require higher initial doses (40-60 mg daily) to rapidly control inflammation
• Timing: Administer in the morning before 9 am to minimize HPA axis suppression, as this aligns with the body's natural cortisol peak between 2-8 am 1
• With food: Take with meals or milk to reduce gastric irritation 1

Treatment Duration and Tapering

The critical benchmark is achieving disease control while reducing to ≤7.5 mg/day prednisone within 3-4 months 2, 3. This threshold is clinically significant because:

• Doses >7.5 mg/day carry substantial risk of corticosteroid-related complications including osteoporosis, metabolic effects, and adrenal suppression 1
• If you cannot taper below 0.15 mg/kg (approximately 10 mg for average adults) within 4 weeks, this signals the need for steroid-sparing immunosuppressive therapy 3

Tapering Protocol

• Decrease dosage in small increments at appropriate intervals once favorable response is noted 1
• Monitor constantly for disease flares during taper
• Never stop abruptly - gradual withdrawal is essential to prevent adrenal insufficiency, which may persist up to 12 months after prolonged high-dose therapy 1

When to Add Steroid-Sparing Agents

Initiate immunosuppressive therapy early if:

• Unable to taper prednisone to ≤7.5-10 mg/day within 3-4 months
• Disease remains active despite adequate corticosteroid dosing
• Recurrent flares occur during tapering attempts

First-Line Steroid-Sparing Options

The 2018 FOCUS guidelines provide clear hierarchy 2:

1. Methotrexate (Grade B) - considered first-line conventional immunosuppressant, particularly for JIA-associated uveitis 3
2. Mycophenolate mofetil (Grade C) - comparable efficacy to methotrexate with 84.6% achieving prednisone ≤10 mg/day at one year 4
3. Adalimumab (Grade A) - strongest evidence among biologics for noninfectious uveitis 2

Critical Monitoring Requirements

During corticosteroid therapy:

• Bone health: Initiate calcium, vitamin D, and bisphosphonate therapy if treatment ≥3 months anticipated at ≥5 mg prednisone equivalent 1
• Intraocular pressure: Monitor if therapy exceeds 6 weeks 1
• Infection risk: Patients are immunosuppressed - avoid exposure to chickenpox/measles 1
• Adrenal function: Consider stress-dose steroids for up to 12 months after discontinuation if patient experiences physiologic stress 1

Common Pitfalls to Avoid

1. Prolonged high-dose monotherapy: Continuing prednisone >10 mg/day beyond 4 weeks without adding steroid-sparing agents leads to cumulative toxicity
2. Abrupt discontinuation: Always taper gradually to prevent withdrawal syndrome (myalgia, arthralgia, malaise) and adrenal crisis 1
3. Evening dosing: Administering corticosteroids in the evening maximally suppresses the HPA axis 1
4. Inadequate bone protection: Failing to implement osteoporosis prevention in patients requiring ≥3 months of therapy 1

Special Considerations

For posterior/intermediate/panuveitis: These anatomic locations typically require more aggressive initial therapy and earlier introduction of steroid-sparing agents compared to isolated anterior uveitis 2. Recent evidence suggests combination therapy (conventional immunosuppressant + TNF inhibitor) achieves superior outcomes compared to conventional agents alone, with 61.1% success at 12 months versus 44.9% for conventional therapy alone 5.